I. Boucot

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

François Maltais, Leif Bjermer, Edward Kerwin et al. · Respiratory Research · 2019 · 115 citations · Full text

Defining the “Frequent Exacerbator” Phenotype in COPD

Olivier Le Rouzic, Nicolás Roche, Alexis B. Cortot et al. · CHEST Journal · 2017 · 93 citations

Inflammatory Lung Disease, Advanced Lung Disease, Lung Inflammation +5

Evaluation of nasopharyngeal cultures for bacteriologic assessment of acute otitis media in children

P Géhanno, G. Lenoir, B. Barry et al. · The Pediatric Infectious Disease Journal · 1996 · 85 citations

Annual direct medical cost of active systemic lupus erythematosus in five European countries

Andrea Doria, Zahir Amoura, Ricard Cervera et al. · Annals of the Rheumatic Diseases · 2012 · 82 citations · Full text

[The AIRE Study: data analysis of 753 European children with asthma].

F.–X. Blanc, Nicolas Postel‐Vinay, I. Boucot et al. · PubMed · 2002 · 57 citations